PAK1 and cardiac hypertrophy: FTY720, an FDA-approved sphingosine derivative, is protective in several models of cardiac hypertrophy and proposed to function through activation of cardiomyocyte PAK1 as its antihypertrophic effects are not observed in PAK1 conditional knockout mice [86].